Tumour infiltrating lymphocytes: Insights into tumour immunology and potential therapeutic implications

Journal of Clinical Pathology - Clinical Molecular Pathology

Volumn 49, Issue 5, 1996, Pages

  Yoong, K F ^a   Adams, D H ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNOLOGY;

EID: 0029822833     PISSN: 13552910     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.49.5.m256     Document Type: Review

References (152)

1. Nathanson L. Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features and possible mechanisms. Conference on Spontaneous Regression of Cancer. Natl Cancer Inst Monogr 1976;44:66-7.
2. Bodurtha AJ. Spontaneous regression of malignant melanoma. In: Clark WH Jr, Goldman LI, Mastrangelo MJ, eds. Human malignant melanoma. New York: Grune and Stratum, 1979:227-41.
3. Underwood JCE. Lymphoreticular infiltration in human tumours: prognostic and biological implication: A review. BrJ Cancer 1974;30:538-48.
4. Svennevig JL, Lunde OC, Hoher J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984;49:375-7.
5. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous cell carcinomas of the head and neck: correlations with extent of tumor and prognosis. Owl Head Neck Surg 1986;95: 142-52.
6. Penn I. Tumours arising in organ transplant recipients. Adv Cancer Res 1978;28:31-61.
7. Ho M, Jaffe R, Miller G, Breinig MK, Dummer JS, Makowka L, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative disorders after transplantation and its manifestations in children. Transplantation 1988;45:719-27.
8. Yamamoto K, Masuko K, Takahashi S, et al. Accumulations of distinct T cell clonotypes in human solid tumours. J Immunol 1995;154:1804-9.
9. Ohmen JD, Moy RL, Zovich D, et al. Selective accumulations of T cell receptor V- gene usage in skin cancer. J Invest Dermatol 1994;6:751-7.
10. Scholler J, Strafen PT, Birck A, et al. Analysis of T cell receptor a- variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother 1994;39:239-48.
11. Witte ON, Boon T Cancer: Editorial overview. Curr Opin Immunol 1995;7:657-8.
12. Morgan DA, Ruscetti FW, Gallo RG. Selective in vivo growth of T lymphocytes from normal bone marrow. Science 1976;193:1007-8.
13. Smith KA. Interleukin-2: Inception, impact and implications. Science 1988;240:1169-76.
14. Yron I, Wood TA, Speiss PJ, Rosenberg SA. In vitro growth of murine T cells: The isolation and growth of lymphoid cells infiltrating syngeneic solid tumours. J Immunol 1980; 125:238-45.
15. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 1980;125:1487-93.
16. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumour infiltrating lymphocytes. Science 1986;233:1318-21.
17. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumour activity of tumour infiltrating lymphocytes expanded in recombinant interleukin-2. J Nail Cancer Inst 1987;79:1067-75.
18. Barth RJ Jr, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumour associated antigens identified by tumour infiltrating lymphocytes. J Immunol 1990;144:1531-7.
19. Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumour necrosis factor have a role in tumour regression mediated by murine CD8+ tumour infiltrating lymphocytes. J Exp Med 1991;! 73:647-58.
20. Barth RJ, Mule JJ, Asher AL, et al. Identification of unique tumour associated antigens by tumour infiltrating lymphocytes using tumour specific secretion of interferon gamma and tumour necrosis factor. J Immunol Methods 1992;140:269-79.
21. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J/WWMWO/1987;138:989-95.
22. Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986;46:3011-17.
23. Finke JH, Rayman P, Hart L, et al. Characterisation of tumour infiltrating lymphocyte subsets from human renal cell carcinoma-specific reactivity defined by cytotoxicity, interferon gamma secretion and proliferation. J Immunother 1994;15:91-104.
24. Heo DS, Whiteside TL, Kanbour A, Herberman RB. Lymphocytes infiltrating human ovarian tumours: Role of Leu-19 (NKH1) positive recombinant IL-2-activated cultures of lymphocyte infiltrating human ovarian tumours. J Immunol 1988;140:4042-9.
25. Kooi S, Freedman RS, Rodriguezvillanueva J, et al. Cytokine production by T cell lines derived from tumour infiltrating lymphocytes from patients with ovarian carcinoma: Tumour-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumour cells. Lymphokine Cytok Res 1993; 12: 429-37.
26. Wimmenauer S, Keller H, Rahner S, et al. Phenotypical and functional characteristics of tumour infiltrating lymphocytes from colon carcinomas stimulated with rIL-2 and rIL-4 in vitro: Comparison with lymphocytes of the normal colon mucosa and the peripheral blood. Anticancer Res 1994;14:963-8.
27. Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Clonal analysis and in situ characterisation of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother 1986;23:169-78.
28. Kurnick JT, Kradin RL, Blumberg R, et al. Functional characterisation of T lymphocytes propagated from lung carcinoma. Clin Immunol Immunopathol 1986;38:367-80.
29. Tagaki S, Chen K, Schwanz R, et al. Functional and phenotypic analysis of tumour infiltrating lymphocytes isolated from human primary and metastatic liver tumours and cultured in recombinant interleukin-2. Cancer 1989;63: 102-11.
30. Kuppner MC, Hamou MF, de Tribolet N. Immunohistological and functional analyses of lymphoid infiltrâtes in human glioblastomas. Cancer Res 1988;48:6926-32.
31. Synderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT. T cell in tumour infiltrating lymphocytes of head and neck cancer. Head Neck 1989;ll:331-6.
32. Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Separation, phenotyping and limiting dilution analysis of lymphocytes infiltrating human solid tumors. Int J Cancer 1986;37:803-11.
33. Whiteside TL, Miescher S, MacDonald RH, von Fliedner V. Separation of tumour infiltrating lymphocytes from tumor cells in human solid tumors: A comparison between velocity sedimentation and discontinous density gradients. J Immunol Methods 1986;90:221-33.
34. Yannelli JR. The preparation of effector cells for use in the adoptive cellular immunotherapy of human cancer. J Immunol Methods 1991;139:1-16.
35. Maleckar JR, Friddell CS, Sferruzza A, et al. Activation and expansion of tumour-derived activated cells for therapeutic use. J Nail Cancer Inst 1989;81:1655-60.
36. Kradin RL, Boyle LA, Preffer FI, et al. Tumour-derived interleukin-2 dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother 1987;24:76-85.
37. Skornick Y, Topalian S, Rosenberg SA. Comparative studies of the long term growth of lymphocytes from tumour infiltrates, tumour draining lymph nodes and peripheral blood by repeated in vitro stimulation with autologous tumour. J BiolRespModifl9<)Q;9-A3\-8.
38. Topalian SL, Soloman D, Rosenberg SA. Tumour-specific lysis by lymphocytes infiltrating melanomas. J Immunol 1989;142:3714-25.
39. Itoh K, Platsoucas CD, Balch CM. Autologous tumourspecific cytotoxic lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin-2 and autologous tumour cells and involvement of the T cell receptor. J Exp Med 1988; 168:1419-41.
40. Cardi G, Mastrangelo MJ, Berd D. Deletion of T cells with the CD4+ CD45RA+ phenotype in lymphocytes that infiltrate subcutaneous métastases of human melanoma. Cancer Res 1989;49:6562-5.
41. Finke JH, Tubbs R, Connely B, et al. Tumour infiltrating lymphocytes in patients with renal cell carcinoma. Ann NY AcadSci 1988;532:387-94.
42. Bilik R, Mor C, Hazaz B, et al. Characterisation of T lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 1989;28:144-7.
43. Rabinowich H, Cohen R, Bruderman L, et al. Functional analysis of mononuclear cells infiltrating into tumours: Lysis of autologous human tumour cells by cultured infiltrating lymphocytes. Cancer Res 1987;47:173-7.
44. Freedman RS, Tomasovic B, Templin S, et al. Large scale expansion in interleukin-2 of tumour-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 1994;167:145-60.
45. Whiteside T. Tumour infiltrating lymphocytes as antitumour effector cells. Biotherapy 1992;5:47-61.
46. Yoong KF, Williams A, Hubscher SG, et al. Expression of endothelial adhesion molecules and T-cell homing receptors in human hepatic tumors [abstract]. FASEB J 1996;10:A1429.
47. Weiss L. Cell adhesion molecules-a critical examination of their role in metastasis. Invas Metast 1994; 14:192-7.
48. Tang DG, Honn KV. Adhesion molecules and tumour metastasis-an update. Invas Metast 1994;14:109-22.
49. Stewart T, Tsai SCJ, Grayson H, et al. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;346:796-8.
50. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994;343: 831-6.
51. Adams DH, Yannelli J, Newman W, et al. Adhesion of tumour-infiltrating lymphocytes to endothelium: A phenotypic and functional analysis [abstract]. Immunology 1994;83:10.
52. Salmi M, Grenman R, Grenman S, et al. Tumour endothelium selectively supports the binding of IL-2 propagated tumour-infiltrating lymphocytes. J Immunol 1995;154: 6002-12.
53. Cozzolino F, Torcia M, Carossino AM, et al. Characterisation of cells from invaded lymph nodes in patients with solid tumours. Lymphokine requirement for tumourspecific lymphoproliferative response. J Exp Med 1987;166: 303-18.
54. Mukherji B, Wilhelm SA, Guha A, et al. Regulation of cellular immune response against autologous human melanoma. Evidence for cell-mediated suppression of in vivo immune response. J Immunol 1986;136:1888-92.
55. Miescher S, Stoeck M, Whiteside TL, et al. Altered activation pathways in T lymphocytes infiltrating human solid tumours. Transplant Proc 1988;20:344-6.
56. Miescher S, Stoeck M, Qiao L, et al. Proliferative and cytolytic potentials of purified human tumour infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T cell receptor expression. Int J Cancer 1988; 42:659-66.
57. Vitolo D, Zerbe T, Kanbour A, et al. Expression of mRNA for cytokines in tumour-infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer. Int J Cam:erl992;51:573-80.
58. Vitolo D, Letessier EM, Johnson JT, et al. Immunologie effector cells in head and neck cancer. J Nad Cancer Inst 1992;13:203-11.
59. Gingras MC, Roussel E, Roth JA, et al. Little expression of cytokine mRNA by fresh tumour-infiltrating mononuclear leucocytes from glioma and lung adenocarcinoma. Cytokine 1995;7:580-8.
60. Schwartzentruber DJ, Topalian SL, Mancini MJ, et al. Specific release of granulocyte-macrophage colony-stimulating factor, tumour necrosis factor-ex, and IFN-gamma by human tumour infiltrating lymphocytes after autologous tumour stimulation. J Immunol 1991; 146:153-64.
61. Guilloux Y, Viret C, Gervois N, et al. Defective lymphokine production by most CD8+ and CD4+ tumour-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumour cells in vitro. EUT J Immunol 1994;24:1966-73.
62. Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perform deficient mice. Nature 1994;369:31-7.
63. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
64. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the fas ligand, a novel member of the tumour necrosis factor family. Cell 1993;75:1169-78.
65. Kagi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
66. Miescher S, Whiteside TL, Carrel S, et al. Functional properties of tumour infiltrating and blood lymphocytes in patients with solid tumours: effects of tumour cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986;136:1899-907.
67. Ostenstad B, Sioud M, Schlichting E, et al. Freshly isolated tumour infiltrating lymphocytes have a high cytotoxic potential, as measured by their ability to induce apoptosis in the target cell. ScandJ Immunol 1995;41:42-8
68. Mizoguchi H, O'Shea JJ, Longo DL, et al. Alterations in signal transduction molecules in T-lymphocytes from tumourbearing mice. Science 1992;258:1795-8.
69. Loeffler CM, Smyth MJ, Longo DL, et al. Immunoregulation in cancer-bearing hosts: Downregulation of gene expression and cytotoxic function in CD8+ T cells. J Immunol 1992;149:949-56.
70. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor Ç chain in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-16.
71. Nakagomi H, Petersson M, Magnusson I, et al. Decreased expression of the signal-transducing Çchains in tumorinfiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993;53:5610-12.
72. Farace F, Angevin E, Vanderplancke J, et al. The decreased expression of CD3 zeta chains in cancer patients is not reversed by IL-2 administration. Ira J Cancer 1994;59:752-5.
73. Ghosh P, Sica A, Young HA, et al. Alterations in NF-KappaB/Rel family proteins in splenic T cells from tumourbearing mice and reversal following therapy. Cancer Res 1994;54:2969-72
74. Wang Q, Stanley J, Kudoh S, et al. T cell infiltrating non-Hodgkin's lymphoma show altered tyrosine phosphorylation pattern even though T cell receptor CD3associated kinases are present. J Immunol 1995;!55: 1382-92.
75. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990;248:1349-55.
76. Van Seventer GA, Shimizu Y, Shaw S. Role of multiple accessory molecules in T-cell activation. Curr Opin Immunol 1991;3:294-303.
77. Chen L, McGowan P, Ashe S, et al. Tumor immunogenecity determines the effect of B7 costimulation on T-cellmediated tumor immunity. J Exp Med 1994;179:523-32.
78. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 1995;7:682-6.
79. Kudoh S, Stanley J, Edinger M, et al. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int J Cancer 1994;58:369-75.
80. Neckers LM, Cossman J. Transferrin receptor induction in mitogen-stimulated human T lymphocytes is required for DNA synthesis and cell division and is regulated by interleukin-2. Proc Natl Acad Sei USA 1983;80:3494-8.
81. Wrann M, Bodmer S, de Martin R, et al. T cell suppressor factor from human glioblastoma cells is a 12.5 Kd protein closely related to transforming growth factor . EMBO J 1987;6:1633-6.
82. Botha JH, Robinson KM, Ramchurren N, et al. Human oesophageal carcinoma cell lines: Prostaglandin production, biologic properties and behaviour in nude mice. J Natl Cancer Inst 1986;76:1053-6.
83. Cianciolo GJ, Copeland TD, Oroszlan S, Synderman R. Inhibition of lymphocyte proliferation by synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453-5.
84. Robb RJ. The suppressive effect of gangliosides upon IL-2 dependent proliferation as a function of inhibition of IL-2 receptor association. J Immunol 1986;136:971-6.
85. Nitta T, Oksenberg JR, Rao RA, et al. Predominant expression of T cell receptor V alpha 7 in tumour-infiltrating lymphocytes of uveal melanoma. Science 1990;249:672-4.
86. Nitta T, Sato K, Okumura K, et al. An analysis of T.cell receptor variable region genes in tumour-infiltrating lymphocytes within malignant tumours. Int J Cancer 1991; 49:545-50.
87. Weidmann E, Elder EM, Trucco M, et al. Usage of T cell receptor V beta chain genes in fresh and cultured tumourinfiltrating lymphocytes from human melanoma. Int J Cancer 1993;54:383-90.
88. Yasumura S, Weidmann E, Hirabayashi H, et al. HLA restriction and T cell receptor V gene expression of cytotoxic T lymphocytes reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 1994;57: 297-305.
89. Weidmann E, Whiteside TL, Giorda R, et al. The T cell receptor V beta gene usage in tumour-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res 1992;52:5913-20.
90. Mitropoulos D, Kooi S, Rodriguezvillanueva J, et al. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes and TIL-derived T cell lines from patients with renal cell carcinoma. Clin Exp Immunol 1994;97:3217.
91. Ebato M, Nitta T, Yagita H, et al. Shared amino acid sequences in the ND-beta-N and N-alpha regions of the T cell receptor of tumour-infiltrating lymphocytes within malignant glioma. Eur J Immunol 1994;24:2987-92.
92. Salvi S, Segalla F, Rao S, et al. Overexpression of T cell receptor beta chain variable region TCRBV14 in HLA-A2matched primary human melanoma. Cancer Res 1995;55: 3374-9.
93. Sim GK. Intraepithelial lymphocytes and the immune system. Adv Immunol 1995;58:297-343.
94. Ikeda H, Sato N, Matsuura A, et al. Analysis of T cell receptor V region gene usage of cytotoxic T lymphocytes and tumour-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas. Cancer Res 1993;53:3078-84.
95. Mackensen A, Ferradini L, Carcelain G, et al. Evidence for in situ amplification of cytotoxic T lymphocytes with antitumour activity in a human regressive melanoma. Cancer Res 1993;53:3569-73.
96. Weidmann E, Logan TF, Yasumura S, et al. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumour cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes. Cancer Res 1993;53:4745-7.
97. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long lasting antitumour immunity. Proc NatlAcad Sei USA 199390:3539-43.
98. Huang AYC, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumour antigens. Science 1994;264:961-5.
99. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone-definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
100. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
101. Street NE, Schumacher TA, Fong H, et al. Heterogeneity of mouse helper T cell: evidence from bulk cultures and limiting dilution cloning for precursors of Thl and Th2 cells. J Immunol 1990;144:1629-39.
102. McAdam AJ, Pulaski BA, Harkins SS, et al. Synergistic effects of coexpression of the Thl cytokines IL-2 and IFNgamma on generation of murine tumour reactive cytotoxic cells. Int J Cancer 1995;61:628-34.
103. Ghosh P, Komschlies KL, Cippitelli M, et al. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumour growth. J Natl Cancer Inst 1995;87:1478-83.
104. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of Thl CD4+ cells through IL-12 produced by Listeriainfected macrophages. Science 1993260:547-9.
105. Fallarino F, Uyttenhove C, Boon T, et al. Endogenous IL-12 is necessary for rejection of P815 tumour variants in vivo. J Immunol 1996;156:1095-100.
106. Heo DS, Whiteside TL, Johnson JT, et al. Long term interleukin-2 dependent growth and cytotoxic activity of tumour-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 1987;47: 6353-62.
107. Yoo YK, Heo DS, Hâta K, et al. Tumour infiltrating lymphocytes from human colon carcinomas. Functional and phenorypic characteristics after long term culture in recombinant interleukin-2. Gastroenterology 1990;98:259-68.
108. Beldegrun A, Muul LM, Rosenberg SA. Interleukin-2 expanded tumour infiltrating lymphocytes in human renal cell cancer. Isolation, characterisation and anti-tumour activity. Cancer Res 1988;48:206-14.
109. loannides CG, Platsoucas CD, Rashed S, et al. Tumour cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991;51:4257-65.
110. Shimizu Y, Weidmann E, Iwatsuki S, et al. Characterization of human auto-tumor-reactive T cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res 1991;51:6153-62.
111. Koo AS, Tso CL, Shimabukuro T, et al. Autologous tumour-specific cytotoxicicty of tumour-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 1991;10:347-54.
112. Tso CL, Ducken T, de Kernion JB, et al. Modulation of tumour-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. J Immunother 1992;12;82-9.
113. Lee TY, Koo AS, Penret C, et al. The effects of interleukin-6 on tumour-infiltrating lymphocytes derived from human renal cell cancer. J Urol 1991;145:663-7.
114. Ditonno P, Tso CL, de Kernion JB, et al. Regulatory effects of interleukin-7 on renal tumour-infiltrating lymphocytes. Urol Res 1992;20:205-10.
115. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin-4 promotes the growth of tumour-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988;168:2183-91.
116. Marcus SG, Perrylalley D, Mule JJ, et al. The use of interleukin-6 to generate tumour infiltrating lymphocytes with enhanced in vivo antitumour activity. J Immunother 1994;15:105-12.
117. Shimizu Y, Iwatsuki S, Herberman RB, et al. Effects of cytokines on in vitro growth of tumour-infiltrating lymphocytes obtained from human primary and metastatic liver tumours. Cancer Immunol Immunother 1991;32:280-8.
118. Townsend A, Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 1989;7: 601-24.
119. Herin M, Lemoine C, Weymants P, et al. Production of stable cytolytic T cell clones directed against autologous human melanoma. Int J Cancer 1987;15:390-6.
120. Crowley NJ, Slingluff CL, Darrow TL, et al. Generation of human autologous melanoma-specific cytotoxic T cells using HLA-A2 matched allogeneic melanomas. Cancer Res 1990;50:492-8.
121. Hald J, Rasmussen N, Claesson MH. Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 1995;41:243~50.
122. Van der Bruggen P, Traversari C, Chômez P, et al. A gene encoding an antigen recognised by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
123. Gaugier B, van den Eynde B, van der Bruggen, et al. Human gene MAGE-3 codes for an antigen recognised on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994;179:92\-30.
124. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognised by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95.
125. Wolfel T, Van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognised on HLA-A2 melanomas by autologous cytolytic T lymphocytes. EurJImmunol 1994;24:75964.
126. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognised by tumour infiltrating lymphocytes associated with in vivo tumour rejection. Proc NatlAcad Sei USA 1994;91:6458-62.
127. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanoma lineage-specific antigen gp 100 is recognised by melanomaderived tumour infiltrating lymphocytes. J Exp Med 1994; 179:1005-9.
128. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognised by the majority of HLA-A2 restricted tumour infiltrating lymphocytes. J Exp Med 1994;180:347-52.
129. Kawakami Y, Elihayu S, Delgado CH, et al. Cloning of the gene coding for a snared human melanoma antigen recognised by autologous T cells infiltrating tumours. Proc Nad AcadSciUSA 1994;91:3515-19.
130. Coulie PG, Brichard V, Van Pel A, et al. A new gene encoding for a differentiation antigen recognised by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Medl994;180:35-42.
131. Wang RF, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumour antigen recognised by HLA-A31 restricted tumour infiltrating lymphocytes. J Exp Med 1995;181:799-804.
132. Zakut R, Topalian SL, Kawakami Y, et al. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 1993;53:5-8.
133. Robbins PF, El-Gamil M, Kawakami Y, et al. Recognition of tyrosinase by tumour infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54: 3124-6.
134. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognise a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sei USA 1994;91:9461-5.
135. Li Y, McGowan P, Hellstrom I, et al. Costimulation of tumour-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be utilised to treat established mouse melanoma. J Immunol 1994;153:421-8.
136. Mattes MJ, Thomson TM, Old LJ, et al. A pigmentationassociated differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 1983;32:717-21.
137. Vijayasyradhi S, Bouchard BB, Houghton AN. The melanoma antigen gp75 is the human homologue to mouse b (BROWN) locus gene, jf Exp Med 1990;171:1375-80.
138. Boon T, Gajewski TF, Coulie PG. From defined human tumour antigens to effective immunization? Immunol Today 1995;16:334-6.
139. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibilty complexunrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc Natl Acad Sei USA 1989;86:7159-63.
140. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T lymphocytes derived from patients with breast adenocarci-noima recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
141. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumour infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. K EnglJMed 1988;319:1676-81.
142. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumour-infiltrating lymphocytes and interleukin-2. J Karl Cancer Inst 1994;86:1159-66.
143. Kradin RL, Kurnick JT, Lazarus DS, et al. Tumour infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;i:577-80.
144. Dillman RO, Oldham RK, Earth NM, et al. Continous interleukin-2 and tumour infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer 1991;68:l-8.
145. Hanson J, Petit R, Walker M, et al. Phase II study of tumour infiltrating lymphocytes (TIL) therapy with bolus recombinant interleukin-2 in metastatic melanoma [abstract]. ProcAm Soc Clin Oncol 1991;10:295.
146. Markowitz A, Parkinson D, Itoh K, et al. Phase I B study of tumour infiltrating lymphocytes (TIL) combined with recombinant interferon-a 2A, recombinant interleukin-2 and cyclophosphamide in patients with advanced renal cell carcinoma and malignant melanoma [abstract]. Proc Am Soc Clin Oncol 1991;10:216.
147. Ravaud A, Legrand E, Delaimay MM, et al. A phase I trial of repeated tumour infiltrating lymphocytes (TIL) infusion in metastatic melanoma. BrJ Cancer 1995;71:331-6.
148. Bukowski RM, Sharfman W, Murthy S, et al. Clinical results and characterization of tumour-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma. Cancer Rex 1991;51:4199-205.
149. Kradin RL, Boyle LA, Preffer FI, et al. Tumour-derived interleukin-2 dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunothcr 1987;24:76-85.
150. Pockaj BA, Sherry RM, Wei JP, et al. Localisation of indium-Ill labelled tumour-infiltrating lymphocytes to tumour in patients receiving adoptive immunotherapy. Cancer 1994;73:1731-7.
151. Yamaue H, Kashmiri SVS, Defilippi R, et al. Enhanced interleukin-2 production in human tumour infiltrating lymphocytes engineered by 3'-truncated interleukin gene. J Immunother 1994;16:262-74.
152. Treisman J, Hwu P, Yannelli JR, et al. Up-regulation of tumour necrosis factor-a production by retrovirally transduced human tumour infiltrating lymphocytes using transretinoic acid. Cell Immunol 1994;156:448-57.